Allergan Unlimited Company, formerly Allergan Limited, is an Ireland-based pharmaceutical company. The Company is focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world. The Company's products primarily focus on four key therapeutic areas, including medical aesthetics, eye care, central nervous system and gastroenterology.

Employees

Sector

Pharmaceuticals

More about the company

01/09	Allergan Aesthetics Launches Skinmedica Barrier Calming Cream and Ha5 Hydra Collagen Facial Mist	CI
08/04	Allergan Aesthetics Opens New Ami Training Center in Austin	CI

Market Cap	6.37TCr 5.51TCr 5.21TCr 4.72TCr 8.86TCr 6,10700Cr 8.93TCr 62TCr 24TCr 3,09600Cr 24TCr 23TCr 9,87500Cr	P/E 2018	-8.76x	P/E 2019	-11.9x
Enterprise Value	8.1TCr 7.01TCr 6.63TCr 6TCr 11TCr 7,76600Cr 11TCr 79TCr 30TCr 3,93800Cr 30TCr 30TCr 12,55900Cr	EV / Sales 2018	4.24x	EV / Sales 2019	4.98x
Free-Float	99.9%	Yield 2018	2.15%	Yield 2019	1.55%

01/09	Allergan Aesthetics Launches Skinmedica Barrier Calming Cream and Ha5 Hydra Collagen Facial Mist	CI
08/04	Allergan Aesthetics Opens New Ami Training Center in Austin	CI
31/03	Allergan Aesthetics Announces Fourth Annual CoolMonth With Deals On CoolSculpting	CI
30/03	Allergan Aesthetics Presents Findings on Safety and Efficacy of Repeat Trenibote Treatments and Data on Medical Weight Loss Aesthetics Patient Behaviors At the 2026 American Academy of Dermatology Meeting	CI
19/03	Allergan Aesthetics Reveals Evolution in Approach to Modern Aesthetic Treatments with Comprehensive Global Survey and New Educational Solutions	CI
04/03	Allergan Aesthetics Shares Medical Weight Loss Data and the Changing Profile of Patients	CI
12/11	Allergan Aesthetics Unveils New Data at 2025 American Society for Dermatologic Surgery Annual Meeting Showcasing Transformative Innovation and Portfolio Excellence	CI
25/25/25	AllAllergan Aesthetics to Showcase Multimodal Treatment Approach and Continued Commitment to Skin Quality At AMWC Dubai	CI
19/25/19	Allergan Aesthetics Unveils Its Newest Hydration Hero	CI
30/25/30	U.S. Food and Drug Administration Accepts for Review Allergan Aesthetics Premarket Approval Application for Skinvive by Juvederm for the Improvement of Neck Appearance	CI
12/25/12	Allergan Aesthetics to Launch Three New Training Centers in the U.S. Expanding Access to High Quality Aesthetics Training	CI
19/24/19	BOTOX® Cosmetic (onabotulinumtoxinA) Receives FDA Approval for Moderate to Severe Vertical Bands Connecting the Jaw and Neck (Platysma Bands)	CI
27/24/27	Allergan Aesthetics Announces the Launch of Its Next Generation Hydration Product: Skinmedica HA5 Hydra Collagen Replenish + Restore Hydrator	CI

01/24/01	Court Dismisses Class Action Against Biopharmaceutical Company For Failing To Disclose Progress Of Competitor; Second Circuit Affirms Dismissal Of Putative Class Action Against Allergan; Eleventh Circuit Affirms That "Toxic" Lender Qualified As A "Dealer" Under The Exchange Act Due To High-Volume Trading; Delaware Court Of Chancery Invalidates Governance Rights In Stockholder Agreement	AQ
20/22/20	Allergan, an AbbVie Company, to Present New Data from its Eye Care Portfolio at the 2022 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting	AQ
06/22/06	Allergan, an AbbVie Company, Announces Positive Topline Phase 3 Results Evaluating Investigational Twice-Daily Administration of VUITY 1.25% in Adults with Age-Related Blurry Near Vision	AQ
22/22/22	AbbVie and Allergan Aesthetics to Present New Research Across Dermatology Portfolio at 2022 AAD Annual Meeting	AQ
10/21/10	Allergan - VUITY 1.25%, the First and Only FDA-Approved Eye Drop to Treat Age-Related Blurry near Vision, is Now Available	AQ

20/21/20	Planète Bourse : La revue de presse du mardi 20 avril 2021
07/20/07	EN DIRECT DES MARCHES : Air France KLM, ArcelorMittal, Legrand, Natixis, Peugeot, Eurofins, Zalando, Facebook...
07/20/07	La Chine repart, mais Washington veille
06/20/06	EN DIRECT DES MARCHES : Danone, Sanofi, Crédit Agricole, Arkema, Neoen, Eurofins, BMW, Novo Nordisk...
06/20/06	Trump franchit le Rubicon

Actavis PLC Share Price NYSE

Stocks

IE00BD1NQJ95

Pharmaceuticals

Valuation: Actavis PLC

Latest news: Actavis PLC

Press Releases: Actavis PLC

News in other languages: Actavis PLC

Managers and Directors: Actavis PLC

Other Pharmaceuticals

Financials

Company Profile

Manager	Title	Age	Since
Alex Thurman DFI	Director of Finance/CFO	56	01/12/2016
Robert Michael PSD	President	55	08/05/2020

Director	Title	Age	Since
Robert Michael BRD	Director/Board Member	55	08/05/2020
Scott Reents BRD	Director/Board Member	-	08/05/2020
Ryan Quigley BRD	Director/Board Member	-	08/05/2020

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ELI LILLY AND COMPANY	-0.19%	+1.09%	+51.85%	+97.36%	1,01500Cr
JOHNSON & JOHNSON	+0.33%	-0.71%	+50.62%	+65.50%	64TCr
ABBVIE INC.	+0.49%	+5.73%	+20.88%	+72.92%	46TCr
ROCHE HOLDING AG	-0.22%	+2.88%	+38.48%	+37.98%	35TCr
NOVARTIS AG	-0.07%	+1.82%	+16.57%	+23.39%	26TCr
ASTRAZENECA PLC	-0.31%	+2.02%	+6.15%	+10.75%	25TCr
AMGEN INC.	-1.53%	-4.46%	+36.90%	+44.08%	21TCr
NOVO NORDISK A/S	-1.60%	-5.51%	-22.30%	-58.60%	19TCr
GILEAD SCIENCES, INC.	+0.49%	-0.23%	+30.00%	+93.34%	18TCr
Average	-0.08%	-1.08%	+25.46%	+42.97%	39.67TCr
Weighted average by Cap.	+0.40%	+0.00%	+34.47%	+59.30%

	2018	2019
Net sales	1.58TCr 1.37TCr 1.29TCr 1.17TCr 2.2TCr 1,51400Cr 2.21TCr 15TCr 5.94TCr 77TCr 5.93TCr 5.8TCr 2,44900Cr	1.61TCr 1.39TCr 1.32TCr 1.19TCr 2.24TCr 1,54300Cr 2.26TCr 16TCr 6.05TCr 78TCr 6.04TCr 5.91TCr 2,49600Cr
Net income	-509.64Cr -441.45Cr -417.44Cr -377.92Cr -709.28Cr -49TCr -714.62Cr -4.98TCr -1.92TCr -25TCr -1.91TCr -1.87TCr -79TCr	-527.1Cr -456.57Cr -431.74Cr -390.87Cr -733.58Cr -51TCr -739.1Cr -5.15TCr -1.98TCr -26TCr -1.98TCr -1.94TCr -82TCr
Net Debt	2.19TCr 1.9TCr 1.79TCr 1.62TCr 3.05TCr 2,10000Cr 3.07TCr 21TCr 8.23TCr 1,06500Cr 8.22TCr 8.04TCr 3,39600Cr	1.73TCr 1.5TCr 1.42TCr 1.28TCr 2.41TCr 1,66000Cr 2.43TCr 17TCr 6.51TCr 84TCr 6.5TCr 6.36TCr 2,68400Cr

End-of-day quote NYSE
- ^USD	-